News

The board of Neuland Laboratories at its meeting held on 12 May 2026 has approved the enhancement of capacity at its Unit 1 located at Bonthapally Village, Gummadidala Mandal, Sangareddy District, Telangana. Existing capacity - 256 KL Existing capacity utilization - 91% Proposed capacity addition - 120.5 KL Period for capacity addition - within 12-18 months Investment required - Rs 143.4 crore (funded through internal accruals and borrowings)

The board of Neuland Laboratories at its meeting held on 12 May 2026 has approved the appointment of Dr. Mauricio Futran (DIN: 11699767) as an Additional Director of the Company, categorized as Non-Executive Non-Independent, w.e.f. 12 May 2026.

Net profit of Neuland Laboratories rose 664.72% to Rs 212.67 crore in the quarter ended March 2026 as against Rs 27.81 crore during the previous quarter ended March 2025. Sales rose 136.40% to Rs 776.25 crore in the quarter ended March 2026 as against Rs 328.36 crore during the previous quarter ended March 2025.For the full year,net profit rose 39.94% to Rs 364.00 crore in the year ended March 2026 as against Rs 260.11 crore during the previous year ended March 2025. Sales rose 36.98% to Rs 2022.99 crore in the year ended March 2026 as against Rs 1476.84 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales776.25328.36 136 2022.991476.84 37 OPM %39.5915.56 -28.4021.89 - PBDT312.5856.19 456 580.72335.48 73 PBT287.4939.30 632 488.98269.93 81 NP212.6727.81 665 364.00260.11 40 Powered by Capital Market - Live News

Neuland Laboratories announced that the 42th Annual General Meeting(AGM) of the company will be held on 4 August 2026.

Neuland Laboratories announced that the Board of Directors of the Company at its meeting held on 12 May 2026, inter alia, have recommended the final dividend of Rs 34 per equity Share (i.e. 340%) , subject to the approval of the shareholders.